AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03960710 — intervention group
Intervention type: OTHER
Intervention: Training (2)
Description: An initial training phase of the artificial intelligence network will be carried out :~- Use of computer data to drive the artificial intelligence network.
Study NCT03960710 — intervention group
Intervention type: OTHER
Intervention: Validation (1)
Description: A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~- Carried out by an intern at the Lyon hospitals
Study NCT06637683 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo COLON
Description: LiveSpo® COLON has a registration number: 10401/2019/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
Study NCT03960710 — intervention group
Intervention type: OTHER
Intervention: Validation (2)
Description: A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~- Carried out by the neural network
Study NCT06637683 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine treatment
Description: The standard internal medicine treatment protocol of the hospital
Study NCT03890094 — intervention group
Intervention type: DRUG
Intervention: Sufentanil
Description: Patients were applied sufentanil and midazolam intravenously and topical anesthetized.
Study NCT03112928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phantom Motor Execution
Description: Neuromotus - PME decodes motor volition applying machine learning to surface electromyography. Once the intention of movement is known, this is use to control serious games in virtual and augmented reality.~A treatment session of MPE consists of:~1. Pain evaluation~2. Placement of the electrodes and fiducial marker~3. Practice of motor execution in Augmented Reality (AR)~4. Gaming using phantom movements~5. Practice of motor execution by matching random target postures of a virtual limb.~Step 3 to 4 are repeated for different phantom joints, initially one at the time progressing to several joints simultaneously. A treatment session last 2 hours.
Study NCT03112928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phantom Motor Imagery
Description: The only difference between PME and PMI is that in the former myoelectric signals are used to give the participants control over the virtual environments, whereas in PMI the presence of myoelectric activity is used as an alarm to remind the participant that it must imagine rather than execute the phantom movement. In PMI the virtual environments act autonomously to guide the participant in imagination of movement.
Study NCT03734107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plan, Reflect, and Engage with Providers for Diabetes Care
Description: Behavioral intervention designed to improve health communication skills and readiness for adult diabetes care
Study NCT00543829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin, docetaxel, tamoxifen
Description: Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion) with tamoxifen (30 mg tablet p.o. for 5 years post surgery)
Study NCT00543829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin, docetaxel
Description: Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion)
Study NCT03018782 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brief Pain Inventory Short Form
Description: Brief Pain Inventory Short Form
Study NCT03088293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
Study NCT03088293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
Study NCT04438746 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Emotion discussion
Description: General discussion of emotions; no therapy or training is offered
Study NCT04438746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Affective Therapy
Description: Active training in regulating anger
Study NCT02028364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10mg orally daily
Study NCT02028364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25mg orally daily
Study NCT03661073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of motor imagery ability
Description: The intervention will last 3 hours ± 45 minutes, the assessment will be spread over 3 sessions of 1 hour ± 15 minutes on one week. The time between two sessions will depend on patient fatigability and availability. The VMIQ-2 and the KVIQ-20 will be realized during the first session. In the second session, patients will perform the hand laterality judgment task and the MIQ-RS. During the last session the Timed up and go and the box and block test will be realized.
Study NCT03661073 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Assessment of motor imagery ability of healthy subject
Description: The intervention will last 2 hours ± 15 minutes. All the tests will be spread over 1 session. Assessment order will be VMIQ-2, KVIQ-20, the hand laterality judgment task, the after a break MIQ-RS, iTUG and iBBT.
Study NCT03124615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide is a FDA and Therapeutic Goods Administration (TGA, Regulatory Authority of therapeutic goods in Australia) approved treatment for castration resistant prostate cancer
Study NCT00610220 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberglass short arm cast
Description: Cast will be applied for a 4-week period
Study NCT00610220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefabricated wrist splint
Description: Splint will be applied for a 4-week period
Study NCT04833738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Study NCT04833738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids Triamcinolone Acetonide
Description: triamcinolone acetonide, 40 mg/ml, single dose
Study NCT04833738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy
Description: electrotherapy
Study NCT01374854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical mesenchymal stem cell (UC-MSCs) infusion
Description: 1×10\^6/kg UC-MSCs is infused through pancreatic artery along with mononuclear cells by interventional therapy and another same dose of UC-MSCs is administered one week post-intervention.
Study NCT01374854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: traditional therapy
Description: exogenous insulin injection daily
Study NCT01739777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ucMSC
Description: 1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma
Study NCT01739777 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Controls
Description: Autologous Serum will administrated as placebo
Study NCT03868228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC)
Description: Use of CapnoPen device to aerosolise Oxaliplatin 92mg/m2 chemotherapy 6-8 weekly intervals for intraperitoneal distribution via laparoscopy.
Study NCT03242278 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: As prescribed by treating physicians
Study NCT03332108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EpxBreastfeeding
Description: We developed an algorithm using the Epharmix platform, an automated toll-free phone and text message-based system that can programmatically query patients via their personal phones and subsequently collect response data, allowing clinically-relevant responses to trigger alerts to designated healthcare providers. The intervention for breastfeeding, hereafter referred to as EpxBreastfeeding, was built using significant clinical and patient input to only ask the most clinically-relevant questions for breastfeeding in a multiple-choice manner, such as In the past \[x\] days, have you fed your baby 1) breast milk only, 2) breast milk and formula or 3) formula only?. These communications elicit patient-reports of breastfeeding at intervals of interest for the provider, which is, on average, every 2 days in the first three weeks postpartum and every 5 days subsequently. All data is filtered by clinician-designed algorithms to stratify patients into categories.
Study NCT04318938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Treatment with Brigatinib
Study NCT04318938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tyrosine kinase inhibitor
Description: Treatment with any TKI
Study NCT03332108 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Baby book survey
Description: We developed a baby book template that will be given to mothers allowing them to make note of dates related to their child's development during the first year. Examples include: When was baby's first appointment with his/her pediatrician? When did you add formula into baby's feeding? When did you start feeding baby only formula? When did you introduce solid food into baby's diet? When did baby first smile? When did you start reading to baby? What was the first book you read to baby? Whe
Study NCT03332108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby book survey
Description: We developed a baby book template that will be given to mothers allowing them to make note of dates related to their child's development during the first year. Examples include: When was baby's first appointment with his/her pediatrician? When did you add formula into baby's feeding? When did you start feeding baby only formula? When did you introduce solid food into baby's diet? When did baby first smile? When did you start reading to baby? What was the first book you read to baby? Whe
Study NCT03771144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthrolysis
Description: Surgery is performed under general anesthesia. The usual duration of this surgery is on average 1h30. This surgery requires an anterior approach and a posterior approach. The patient is placed in lateral decubitus. The arthroscope of 2.7 is introduced by a posterior route. An anterior instrumental track is made from inside out through the rotator interval.
Study NCT03681652 — intervention group
Intervention type: DRUG
Intervention: Azathioprine
Description: Children with Crohn's disease who are treated with azathioprine for post-operative prophylaxis following ileo-cecal resection
Study NCT03681652 — intervention group
Intervention type: DRUG
Intervention: Anti-TNF Drug
Description: Children with Crohn's disease who are treated with anti-TNF monotherapy for post-operative prophylaxis following ileo-cecal resection
Study NCT00527111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT00527111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Study NCT00527111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Study NCT02516813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814 100 mg
Description: Participants received 100 mg of M3814 as capsule or tablet orally once daily.
Study NCT00527111 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic irradiation
Study NCT00527111 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic irradiation
Study NCT02516813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814 200 mg
Description: Participants received 200 mg of M3814 as capsule or tablet orally once daily.
Study NCT02516813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814 300 mg
Description: Participants received 300 mg of M3814 as capsule or tablet orally once daily.
Study NCT02516813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814 400 mg
Description: Participants received 400 mg of M3814 as capsule or tablet orally once daily.
Study NCT02996539 — intervention group
Intervention type: OTHER
Intervention: Clinical examination and laboratory measurements
Description: Subjects were interviewed by a physician regarding their medical history, history of hypoglycemic attacks, smoking status, and alcohol consumption. Concentrations of blood urea nitrogen (BUN) and serum creatinine (SCr) were analyzed by the urease-ultraviolet rate method and picric acid method, respectively. Serum uric acid was determined using the enzymatic colorimetric method. Serum hemoglobin A1c (HbA1c) was measured by liquid enzymatic assay. Urine albumin and urine creatinine were found through immune turbidimetric analysis and the enzymatic method, respectively.
Study NCT02516813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814 50 mg
Description: Participants received 100 mg of M3814 as capsule orally once daily.
Study NCT02516813 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated RT
Description: Participants received fractionated palliative RT (3 Gray \[Gy\] \* 10 in Arm A and 2 Gy \* 33 to 35, 5 fractions per week \[F/W\]) in Arm B and received a single high dose of RT (10-25 Gy) capsule on Day 1 given on Lesion 1 and a single high dose of RT (10-25 Gy) on Day 2 given on Lesion 2 in ancillary CPoP part.
Study NCT02516813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants received Cisplatin twice at a dose of 100 mg/m\^2 or weekly at a dose of 40 mg/m\^2.
Study NCT02244398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FP and HTC services
Description: In this project, VHTs already providing family planning services are trained to offer HIV testing and counseling services (HTC).
Study NCT02244398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FP services
Description: VHTs in the control arm only provide family planning services
Study NCT01838226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving
Description: A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to CVD-related behaviors (e.g., smoking and weight reduction).
Study NCT04391569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: Ganaxolone will be administered.
Study NCT04391569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study NCT03812848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticoagulation Stewardship Program
Description: A clinical-pharmacist led anticoagulation stewardship program that includes:~1. Warfarin monitoring and dosing protocol. 1a.Warfarin initial dosing algorithm. 1b.Recommended International normalized ration (INR) target and duration of Warfarin therapy by indication.~1c.Warfarin dosage adjustment algorithms.~1d.Management of high INR values. 2-Heparin weight-based protocol. 3-Perioperative anticoagulation use protocol. 4-Policies that address baseline and ongoing laboratory monitoring for anticoagulants.~5-Protocol for Heparin Induced Thrombocytopenia(HIT) management. 6-Anticoagulation reversal protocol. 7-Booklet for anticoagulant drugs and all of previously prepared protocols. 8-Education programs regarding anticoagulation's therapy for health care team dealing with anticoagulation and patients.
Study NCT02835105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surotomycin
Description: A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules
Study NCT02835105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral dose of placebo for surotomycin in hard gelatin capsules
Study NCT03470051 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: QT Ultrasound
Description: All subjects will be asked to agree to an ultrasound-guided breast needle biopsy by a qualified radiologist experienced in this procedure if not already completed prior to study entry.
Study NCT04363892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical and infrared imaging
Description: Acquiring images (photographs) of the skin
Study NCT03092518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Heated Intraperitonial Chemotherapy (HIPEC) with gastrectomy using cisplatin, mitomycin C and sodium thiosulfate
Study NCT03092518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (90 mg/m2) will be administered via circuit to the peritoneal cavity
Study NCT03092518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Mitomycin C 10 mg/m2 will be administered via circuit to the peritoneal cavity
Study NCT03092518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Sodium thiosulfate will be administered by continuous intravenous infusion starting immediately prior to the chemotherapy perfusion and continuing for a total of 12 hours.
Study NCT03741673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03741673 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03741673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03741673 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03741673 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study NCT03741673 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study NCT04541927 — intervention group
Intervention type: GENETIC
Intervention: Epigenetic signatures
Description: Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
Study NCT06172023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nanoparticles Irrigant
Description: Nanosilver irrigant solution
Study NCT06172023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Nanoparticles Irrigant
Description: Nanosilver irrigant solution
Study NCT06172023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chitosan Nanoparticles Irrigant
Description: Chitosan nanoparticles irrigant solution
Study NCT06172023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan Nanoparticles Irrigant
Description: Chitosan nanoparticles irrigant solution
Study NCT04012450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural anesthesia
Description: Performing an epidural anesthesia
Study NCT04012450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spina-epidural anesthesia
Description: Performing a spina-epidural anesthesia
Study NCT04190472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IOP HPV test
Description: Immediately after the LEEP, a cervical sample was taken for the IOP-HPV test
Study NCT02583841 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: scaling and root planing as an intervention was done in patients of the test group
Study NCT01495013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1mg Glimepiride/10mg Atorvastatin FDC
Description: 1 tablet by mouth once a day
Study NCT01495013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2mg Glimepiride/10mg Atorvastatin FDC
Description: 1 tablet by mouth once a day
Study NCT03993470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short foot excercise for intrinsec muscles of the foot
Description: to examine the effects of the SFE compared to a placebo exercise in the foot posture index after a daily period of 4 weeks.
Study NCT04229290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Switch of virally suppressed participants to Dolutegravir
Study NCT04229290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: Switch of virally suppressed participants to Dolutegravir
Study NCT02543151 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SpyGlass (direct visualization system) choledochoscopy
Description: SpyGlass (direct visualization system) choledochoscopy procedure will be performed pre and post biliary complication treatment
Study NCT04413968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid detection test
Description: Rapid serological test by taking 3 drops of blood from the fingertip via the TDR device (rapid detection test) for children, supervising nursery staff and hospital laboratory and administrative staff
Study NCT04413968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal swab
Description: Posterior nasopharyngeal swabbing in children